Lin E, Lin CH, Lane HY (2021) Machine learning and deep learning for the pharmacogenomics of antidepressant treatments. Clin Psychopharmacol Neurosci 19(4):577–588

Article  CAS  PubMed  Google Scholar 

McInnes G, Dalton R, Sangkuhl K, Whirl-Carrillo M, Lee SB, Tsao PS et al (2020) Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Comput Biol 16(11):e1008399

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Lee M, Allard WG, Vossen RHAM, Baak-Pablo RF, Menafra R, Deiman BALM et al (2021) Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Sci Transl Med 13(603):eabf3637

Article  PubMed  Google Scholar 

Saab Y, Nakad Z (2023) A software tool to adjust codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions. Pharmacogenomics J 23(6):217–224

Article  CAS  PubMed  Google Scholar 

Nakad Z, Saab Y (2024) Precision dosing for patients on tricyclic antidepressants. Pharmacogenet Genomics 34(4):117–125

CAS  PubMed  Google Scholar 

Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR et al (2023) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharma Therapeutics 114(1):51–68

Article  CAS  Google Scholar 

Mrazek DA, Biernacka JM, O’Kane DJ, Black JL, Cunningham JM, Drews MS et al (2011) CYP2C19 variation and citalopram response. Pharmacogenet Genomics 21(1):1–9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Damle BD, Uderman H, Biswas P, Crownover P, Lin C, Glue P (2009) Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Brit J Clinical Pharma 68(5):682–689

Article  CAS  Google Scholar 

Meloche M, Khazaka M, Kassem I, Barhdadi A, Dubé M, De Denus S (2020) CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis. Brit J Clinical Pharma 86(6):1015–1033

Article  CAS  Google Scholar 

Fux R, Morike K, Prohmer A, Delabar U, Schwab M, Schaeffeler E et al (2005) Impact of genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78(4):378–387

Article  CAS  PubMed  Google Scholar 

Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F (1981) E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 30(2):189–193

Article  PubMed  Google Scholar 

Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E et al (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Brit J Clinical Pharma 65(5):767–774

Article  CAS  Google Scholar 

Batty JA, Hall AS, White HL, Wikstrand J, De Boer RA, Van Veldhuisen DJ et al (2014) An Investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. Clin Pharmacol Ther 95(3):321–330

Article  CAS  PubMed  Google Scholar 

Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27(18):1673–1677

Article  CAS  PubMed  Google Scholar 

Dalén P, Dahl ML, Ruiz MLB, Nordin J, Bertilsson L (1998) 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*. Clin Pharmacol Ther 63(4):444–452

Article  PubMed  Google Scholar 

Deodhar M, Turgeon J, Michaud V (2021) Contribution of CYP2D6 Functional Activity to Oxycodone efficacy in pain management: genetic polymorphisms, phenoconversion, and tissue-selective metabolism. Pharmaceutics 13(9):1466

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Skaar TC et al (2014) Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther 96(2):175–181

Article  CAS  PubMed  Google Scholar 

Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S et al (2015) In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Brit J Clinical Pharma 80(5):1122–1130

Article  CAS  Google Scholar 

Zineh I, Beitelshees A, Gaedigk A, Walker J, Pauly D, Eberst K et al (2004) Pharmacokinetics and genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76(6):536–544

Article  CAS  PubMed  Google Scholar 

Mykkänen AJH, Taskinen S, Neuvonen M, Paile-Hyvärinen M, Tarkiainen EK, Lilius T et al (2022) Genomewide association study of simvastatin pharmacokinetics. Clin Pharma and Therapeutics 112(3):676–686

Article  Google Scholar 

Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F et al (2009) Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 65(9):887–894

Article  CAS  PubMed  Google Scholar 

Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M et al (2005) Influence of CYP2D6 genotype on metoprolol plasma concentration and β-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 46(5):713–720

Article  CAS  PubMed  Google Scholar 

Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C (2016) CYP2D6 polymorphisms and their influence on risperidone treatment. PGPM 9:131–147

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rau T, Wuttke H, Michels L, Werner U, Bergmann K, Kreft M et al (2009) Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85(3):269–272

Article  CAS  PubMed  Google Scholar 

Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N et al (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 12(6):465–72

Article  CAS  PubMed  Google Scholar 

Saiz-Rodríguez M, Ochoa D, Herrador C, Belmonte C, Román M, Alday E et al (2019) Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Basic Clin Pharma Tox 124(3):321–329

Article  Google Scholar 

Sharp CF, Gardiner SJ, Jensen BP, Roberts RL, Troughton RW, Lainchbury JG et al (2009) CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenomics J 9(3):175–184

Article  CAS  PubMed  Google Scholar 

Shen Q, Hu C, Miao J, Chen J, Peng Y, Pan T et al (2021) First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study. Eur J Pharm Sci 159:105724

Article  CAS  PubMed  Google Scholar 

Shi HY, Yan J, Zhu WH, Yang GP, Tan ZR, Wu WH et al (2010) Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol 66(11):1131–1136

Article  PubMed  PubMed Central  Google Scholar 

Stingl J, Viviani R (2015) Polymorphism in CYP 2D6 and CYP 2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med 277(2):167–177

Article  CAS  PubMed  Google Scholar 

Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS et al (2005) β-adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure*. Clin Pharmacol Ther 77(3):127–137

Article  CAS  PubMed